DYAI Nasdaq Biological Products, (No Diagnostic Substances) Financials FY2017βFY2025
Dyadic International Inc had $3.1M of revenue in fiscal 2025, down 11.6% on the year before. Over five years, revenue changed +14.0% a year on average.
Last close Β· Oct 23, 2026
$0.40
0.7%Hi! I read Dyadic International Incβs latest annual report (fiscal 2025). Here is what stands out:
Good So-so Weak
Are sales growing?
β11.6%
No. Sales fell 11.6% last year.
Does it make a profit?
β238.3%
No. It lost money last year.
How healthy are the accounts?
1 / 8
Weak. It passes 1 of 8 health tests.
How is the share priced?
β
No P/E: it made no profit over the last four quarters.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Is it selling more, and how much does it keep?
In plain words: Every quarter, companies publish how much they sold and earned. These are the days Dyadic International Inc did it, and the next one. Share prices often move a lot on those days.
Next results
November 11, 2026
Wednesday Β· in 16 days
| Date | Results for | Time | Source |
|---|---|---|---|
| Aug 12, 2026 | Q2 '26 | Before the market opens | 8-K β |
| May 13, 2026 | Q1 '26 | After the market closes | 8-K β |
| Mar 25, 2026 | Q4 '25 | After the market closes | 8-K β |
| Nov 12, 2025 | Q3 '25 | After the market closes | 8-K β |
| Aug 13, 2025 | Q2 '25 | After the market closes | 8-K β |
| May 14, 2025 | Q1 '25 | After the market closes | 8-K β |
| Mar 26, 2025 | Q4 '24 | After the market closes | 8-K β |
| Nov 12, 2024 | Q3 '24 | After the market closes | 8-K β |
From SEC filings: the results press release (8-K) or, without one, the quarterly or annual report.
KIRA Β· Dyadic International Inc had $3.1M of revenue in fiscal 2025, down 11.6% on the year before. Over five years, revenue changed +14.0% a year on average. Its operating margin was β232.8%, down 63.9Β pts: of every 100 in sales, about β233 is left after running the business.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
Revenue
Margins, % of revenue
Margins, % of revenue
KIRA Β· Dyadic International Inc lost $7.4M in fiscal 2025.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
Net income
Diluted EPS
Diluted EPS
How much cash comes in, and where does it go?
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
Cash from operations vs capital spending
Cash from operations vs capital spending
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
Diluted shares outstanding (annual)
KIRA Β· No open-market insider trades in the last 12 months.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Can it carry its debts, and how well does it use its money?
Cash, debt and the ratios that show how comfortably Dyadic International Inc can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $15.7M | $5.8M | $6.5M | $9.3M | $7.3M |
| Current ratio | 8.2x | 5.5x | 3.6x | 4.0x | 2.7x |
| Quick ratio | 8.2x | 5.5x | 3.6x | 4.0x | 2.7x |
| Total assets | $21.3M | $13.7M | $8.2M | $9.9M | $9.9M |
| Total liabilities | $2.9M | $2.6M | $2.3M | $7.5M | $8.7M |
| Shareholders' equity | $18.4M | $11.1M | $5.9M | $2.5M | $1.2M |
| Net debt (β = net cash) | β | β | β | β | β |
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
KIRA Β· Dyadic International Inc passes 1 of 8 financial health tests (Piotroski F-score).
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β | β | β |
| F-score | β / 3 | 4 / 8 | 3 / 8 | 2 / 8 | 3 / 8 | 3 / 7 | 3 / 7 | 4 / 7 | 1 / 8 |
| Accruals ratio | β0.9% | β2.7% | β6.3% | β8.1% | β7.0% | β9.4% | β0.6% | β20.2% | β16.7% |
| Altman Z'' | 71.86 | 55.15 | 24.41 | 16.78 | β2.08 | β12.77 | β31.29 | β27.03 | β31.25 |
Every number, year by year.
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||
| Revenue | $0.8M | $1.3M | $1.7M | $1.6M | $2.4M | $2.9M | $2.9M | $3.5M | $3.1M |
| Gross profit | $0.1M | $0.3M | $0.2M | $0.2M | $0.5M | $0.8M | $0.9M | $2.3M | $0.8M |
| Research and development | $1.8M | $2.1M | $3.1M | $3.9M | $8.4M | $4.5M | $3.3M | $2.0M | $2.2M |
| Operating income | β$7.1M | β$7.6M | β$9.3M | β$10.0M | β$14.7M | β$10.2M | β$8.2M | β$5.9M | β$7.2M |
| Pretax income | β$2.1M | β$6.6M | β$8.3M | β$9.2M | β$13.1M | β$9.8M | β$6.8M | β$5.8M | β$7.3M |
| Income tax | β$0.1M | β$1.0M | $0.0M | $0.0M | $0.0M | β | β | β | β |
| Net income | β$2.1M | β$5.7M | β$8.3M | β$9.3M | β$13.1M | β$9.7M | β$6.8M | β$5.8M | β$7.4M |
| Diluted EPS | β$0.07 | β$0.21 | β$0.31 | β$0.34 | β$0.47 | β | β | β$0.20 | β$0.23 |
| Diluted shares | 0.03B | 0.03B | 0.03B | 0.03B | 0.03B | β | β | 0.03B | 0.03B |
| Cash flow | |||||||||
| Cash from operations | β$1.7M | β$4.4M | β$5.8M | β$6.6M | β$11.3M | β$8.1M | β$6.7M | β$4.0M | β$5.7M |
| Stock-based compensation | $0.6M | $0.5M | $1.2M | $1.7M | $1.8M | $1.9M | $1.2M | $1.1M | $0.9M |
| Share buybacks | $6.2M | $2.3M | $0.0M | β | β | β | β | β | β |
| Dividends and buybacks | $6.2M | $2.3M | $0.0M | β | β | β | β | β | β |
| Balance sheet | |||||||||
| Cash and short-term investments | $5.8M | $2.4M | $4.8M | $20.6M | $15.7M | $5.8M | $6.5M | $9.3M | $7.3M |
| Current assets | $49.6M | $42.7M | $35.6M | $29.8M | $21.0M | $13.4M | $8.1M | $9.8M | $9.9M |
| Current liabilities | $0.8M | $0.8M | $1.6M | $1.6M | $2.6M | $2.4M | $2.3M | $2.4M | $3.7M |
| Total assets | $50.7M | $43.3M | $37.5M | $30.1M | $21.3M | $13.7M | $8.2M | $9.9M | $9.9M |
| Total liabilities | $0.8M | $0.8M | $1.6M | $1.6M | $2.9M | $2.6M | $2.3M | $7.5M | $8.7M |
| Preferred stock | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | β |
| Shareholders' equity | $50.0M | $42.5M | $35.9M | $28.4M | $18.4M | $11.1M | $5.9M | $2.5M | $1.2M |
| Margins | |||||||||
| Gross margin | 10.3% | 20.7% | 13.2% | 11.0% | 19.1% | 27.5% | 31.8% | 65.8% | 24.9% |
| Operating margin | β939.7% | β586.1% | β552.2% | β625.9% | β612.7% | β346.9% | β283.9% | β168.8% | β232.8% |
| Net margin | β281.6% | β439.4% | β494.2% | β582.1% | β543.7% | β332.2% | β234.4% | β166.2% | β238.3% |
| Returns | |||||||||
| Return on capital employed | β14.3% | β17.9% | β25.9% | β35.2% | β78.6% | β90.2% | β137.9% | β78.9% | β114.9% |
| Return on equity | β4.3% | β12.3% | β21.2% | β29.0% | β55.8% | β66.1% | β80.1% | β139.2% | β397.8% |
| Return on assets | β4.2% | β12.1% | β20.6% | β27.6% | β50.9% | β55.6% | β62.0% | β64.0% | β74.1% |
| Return on tangible equity | β4.3% | β13.4% | β23.2% | β32.8% | β71.1% | β87.8% | β115.6% | β235.2% | β597.6% |
| Growth | |||||||||
| Revenue growth | β | 70.8% | 29.8% | β4.7% | 50.1% | 21.9% | β1.1% | 20.6% | β11.6% |
| Share count change | β | β4.3% | β2.4% | 1.7% | 1.3% | β | β | β | 11.3% |
| Financial health | |||||||||
| Current ratio | 64.5x | 50.3x | 22.4x | 18.3x | 8.2x | 5.5x | 3.6x | 4.0x | 2.7x |
| Quick ratio | 64.5x | 50.3x | 22.4x | 18.3x | 8.2x | 5.5x | 3.6x | 4.0x | 2.7x |
| Capital allocation | |||||||||
| Stock comp / revenue | 84.8% | 36.1% | 69.7% | 103.1% | 74.2% | 64.5% | 42.9% | 32.2% | 30.1% |
| Quality scores | |||||||||
| Piotroski F-score | β | 4.0 | 3.0 | 2.0 | 3.0 | 3.0 | 3.0 | 4.0 | 1.0 |
| Altman Z'' | 71.9 | 55.1 | 24.4 | 16.8 | β2.1 | β12.8 | β31.3 | β27.0 | β31.2 |
| Accruals ratio | β0.9% | β2.7% | β6.3% | β8.1% | β7.0% | β9.4% | β0.6% | β20.2% | β16.7% |
Source: SEC EDGAR XBRL filings (CIK 0001213809). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.
